LSM4

Across TCGA pan-cancer cohorts, LSM4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LSM4 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LSM4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LSM4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where LSM4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.794	0.896	.019	7	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →
PDAC	DFS	Tertile	II,III,IV	0.939	0.731	.038	3	view →
LSCC	DFS	Median	II,III,IV	0.811	0.592	.037	1	view →
CCRCC	OS	Quartile	All	0.573	1.000	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LSM4–HNSC (OS)

Open the HNSC breakdown →